RESUMO
PURPOSE: To determine the efficacy of intravitreal injections of ranibizumab in the treatment of retinal angiomatous proliferation (RAP) in neovascular age-related macular degeneration. METHODS: Retrospective, consecutive case series of 26 eyes (26 patients) treated with intravitreal injections of 0.5 mg ranibizumab for RAP. Patients received intravitreal injections at monthly intervals during upload phase for a 3-month period. RESULTS: Mean visual acuity before treatment was 0.75 ± 0.38logMAR (mean ± SD, n = 26). In the upload phase, mean visual acuity improved 4 weeks after the initial injection to 0.6 ± 0.37logMAR (n = 26) and to 0.53 ± 0.34logMAR (n = 26) 4 weeks after the third monthly intravitreal injection of ranibizumab. The mean optical coherence tomography (OCT) central foveal thickness reduced from 345 ± 55 µm at baseline to 215 ± 87 µm at 3 months. In the maintenance phase, mean visual acuity after 6 months was 0.66 ± 0.38logMAR (n = 12) and 0.7 ± 0.37logMAR after 9 months (n = 6). The mean OCT central foveal thickness was 259 ± 59 µm (n = 13) at 6 months and 280 ± 127 µm (n = 6) at nine-month follow-up. CONCLUSION: Intravitreal ranibizumab resulted in an improvement of visual acuity 4 weeks after the first injection but was more pronounced after 3 months. A reduction in leakage and OCT central foveal thickness was seen 3 months after the commencement of treatment.
Assuntos
Inibidores da Angiogênese/uso terapêutico , Angiomatose/tratamento farmacológico , Anticorpos Monoclonais Humanizados/uso terapêutico , Neovascularização Retiniana/tratamento farmacológico , Degeneração Macular Exsudativa/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Angiomatose/diagnóstico , Angiomatose/fisiopatologia , Feminino , Humanos , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Ranibizumab , Neovascularização Retiniana/diagnóstico , Neovascularização Retiniana/fisiopatologia , Retratamento , Estudos Retrospectivos , Tomografia de Coerência Óptica , Resultado do Tratamento , Acuidade Visual/fisiologia , Degeneração Macular Exsudativa/diagnóstico , Degeneração Macular Exsudativa/fisiopatologiaRESUMO
BACKGROUND: To evaluate the effectiveness of transpupillary thermotherapy (TTT) as an adjunct to ruthenium brachytherapy for treatment of choroidal melanoma with reduced radioactive dose. PATIENTS AND METHODS: In a prospective nonrandomised analysis 15 eyes with primary malignant melanoma of the choroid (posterior to the equator, thickness = 4.5 and base = 12 mm) were treated with TTT (diode laser at 810 nm, spot size 2 - 3 mm, energy 0.3 - 0.9 watt, exposure time 21 - 45 minutes) in conjunction with an attenuated ruthenium plaque (radioactive dose to the tumour apex 100 Gy). Follow-up was at least 12 months. RESULTS: The mean tumour thickness before therapy was 3.2 mm (1.2 - 4.5 mm), the mean tumour regression 3 months postoperatively 2.1 mm (0.5 - 4.5 mm). 12 months postoperatively all tumours were regressed through a completely flattened chorioretinal scar. In 5 eyes visual acuity improved. The main reason for visual decrease in 7 eyes was subfoveal tumour location in 4 eyes, development of macular oedema in 2 eyes and epiretinal gliosis in one eye. Neither occlusion of retinal vessels nor radiation retinopathy/optic neuropathy were observed. Despite complete tumour regression clinically and fluoresceinangiographically, ICG-angiography revealed persistence of choriocapillary vessels especially at the posterior margin of the treatment zone in all eyes. No tumour regrowth or metastatic disease were recorded. CONCLUSIONS: Our 12-month results of TTT complementary to ruthenium brachytherapy with an attenuated tumour apex dose of 100 Gy for posterior choroidal melanoma with thickness = 4.5 mm are comparable to findings after TTT alone, especially in regard to regression course, low rate of sideeffects and visual results. ICG angiography might be a useful tool to monitor an eventual tumour regrowth in the choriocapillary layer. For evaluation of sideeffects of brachytherapy a postradiation follow-up of at least 2 - 5 years is mandatory.